Effector Therapeutics Correlations
| EFTR Stock | USD 2.20 0.04 1.85% |
The correlation of Effector Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Effector Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Effector Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Modest diversification
The correlation between Effector Therapeutics and NYA is 0.24 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Effector Therapeutics and NYA in the same portfolio, assuming nothing else is changed.
Effector |
The ability to find closely correlated positions to Effector Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Effector Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Effector Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Effector Therapeutics to buy it.
Moving together with Effector Stock
| 0.71 | VRAX | Virax Biolabs Group Fiscal Year End 12th of June 2024 | PairCorr |
| 0.86 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
| 0.61 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.69 | TXG | 10X Genomics | PairCorr |
| 0.75 | GILD | Gilead Sciences | PairCorr |
| 0.73 | GOSS | Gossamer Bio Earnings Call This Week | PairCorr |
| 0.64 | IMRX | Immuneering Corp Earnings Call This Week | PairCorr |
Moving against Effector Stock
| 0.57 | LIXT | Lixte Biotechnology Earnings Call This Week | PairCorr |
| 0.45 | INDP | Indaptus Therapeutics Financial Report 9th of May 2024 | PairCorr |
| 0.41 | ELVN | Enliven Therapeutics Trending | PairCorr |
Related Correlations Analysis
| 0.69 | -0.5 | -0.65 | 0.13 | INDP | ||
| 0.69 | -0.28 | -0.7 | 0.38 | JSPR | ||
| -0.5 | -0.28 | 0.48 | 0.33 | RNXT | ||
| -0.65 | -0.7 | 0.48 | 0.07 | ENSC | ||
| 0.13 | 0.38 | 0.33 | 0.07 | VRPX | ||
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Effector Stock performing well and Effector Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Effector Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| INDP | 4.55 | 0.43 | 0.07 | 10.00 | 4.96 | 12.90 | 24.83 | |||
| JSPR | 4.00 | 1.13 | 0.28 | 0.57 | 3.73 | 8.90 | 27.11 | |||
| RNXT | 3.91 | 0.07 | 0.01 | 0.16 | 5.38 | 7.52 | 42.62 | |||
| ENSC | 3.90 | (1.21) | 0.00 | 2.63 | 0.00 | 5.45 | 37.06 | |||
| VRPX | 6.44 | (0.20) | 0.00 | 0.22 | 0.00 | 13.00 | 33.87 |
Be your own money manager
Our tools can tell you how much better you can do entering a position in Effector Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Optimization Now
Portfolio OptimizationCompute new portfolio that will generate highest expected return given your specified tolerance for risk |
| All Next | Launch Module |
Effector Therapeutics Corporate Management
Elected by the shareholders, the Effector Therapeutics' board of directors comprises two types of representatives: Effector Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Effector. The board's role is to monitor Effector Therapeutics' management team and ensure that shareholders' interests are well served. Effector Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Effector Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Siegfried Reich | CoFounder Board | Profile | |
| Mayank MD | Chief Officer | Profile | |
| Michael MBA | Chief Officer | Profile | |
| Davide Ruggero | CoFounder Board | Profile | |
| Douglas MD | Chief Officer | Profile | |
| Kevan Shokat | CoFounder Board | Profile |
Already Invested in Effector Therapeutics?
The danger of trading Effector Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Effector Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Effector Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Effector Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Effector Therapeutics is a strong investment it is important to analyze Effector Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Effector Therapeutics' future performance. For an informed investment choice regarding Effector Stock, refer to the following important reports: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Effector Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Effector Stock, please use our How to Invest in Effector Therapeutics guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for Effector Stock analysis
When running Effector Therapeutics' price analysis, check to measure Effector Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Effector Therapeutics is operating at the current time. Most of Effector Therapeutics' value examination focuses on studying past and present price action to predict the probability of Effector Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Effector Therapeutics' price. Additionally, you may evaluate how the addition of Effector Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
Is Effector Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Effector Therapeutics. If investors know Effector will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Effector Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (16.37) | Revenue Per Share 0.349 | Quarterly Revenue Growth 1.17 | Return On Assets (0.85) | Return On Equity (9.47) |
The market value of Effector Therapeutics is measured differently than its book value, which is the value of Effector that is recorded on the company's balance sheet. Investors also form their own opinion of Effector Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Effector Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Effector Therapeutics' market value can be influenced by many factors that don't directly affect Effector Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Effector Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Effector Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Effector Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.